| Biomarker ID | 416 |
| PMID | 18816637 |
| Year | 2009 |
| Biomarker | 2-OHE1-6-N3Ade |
| Biomarker Basis | Concentration Based (pmol/ml) |
| Biomolecule | Metabolites |
| Source | Urine |
| Subjects | Humans |
| Regulation | Upregulated (PCA median: 0.2pmol/ml vs Control median: 0pmol/ml) |
| Odds Ratio/Hazard Ratio/Relative Risk | NA |
| Effect on Pathways | NA |
| Experiment | Prostate Cancer Vs Controls |
| Type of Biomarker | Diagnostic |
| Cohort | Urine samples from 14 patients diagnosed with PCA were taken along with 125 controls |
| Senstivity | NA |
| Specificity | NA |
| AUC | NA |
| Accuracy | NA |
| Level Of Significance | p=0.0014 |
| Method Used | liquid chromatography/tandem mass spectrometry |
| Clinical | No |
| Remarks | With a cut-off value of 50 for the ratio of depurinating estrogen-DNA adducts to their corresponding metabolites and conjugates, the sensitivity is 0.71 with 95% CI of 0.42--0.92, and the specificity is 0.75 with 95% CI of 0.67--0.82. |
| Clinical Trial Number | NA |
| Degree Of Validity | Not validated on independent patient dataset |
| Technical Name | ESR1 |